Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Negat Results Biomed
2009 Jan 12;8:2. doi: 10.1186/1477-5751-8-2.
Show Gene links
Show Anatomy links
Oxaliplatin neurotoxicity--no general ion channel surface-charge effect.
Broomand A
,
Jerremalm E
,
Yachnin J
,
Ehrsson H
,
Elinder F
.
???displayArticle.abstract???
Oxaliplatin is a platinum-based chemotherapeutic drug. Neurotoxicity is the dose-limiting side effect. Previous investigations have reported that acute neurotoxicity could be mediated via voltage-gated ion channels. A possible mechanism for some of the effects is a modification of surface charges around the ion channel, either because of chelation of extracellular Ca2+, or because of binding of a charged biotransformation product of oxaliplatin to the channel. To elucidate the molecular mechanism, we investigated the effects of oxaliplatin and its chloride complex [Pt(dach)oxCl](-) on the voltage-gated Shaker K channel expressed in Xenopus oocytes. The recordings were made with the two-electrode and the cut-open oocyte voltage clamp techniques. To our surprise, we did not see any effects on the current amplitudes, on the current time courses, or on the voltage dependence of the Shaker wild-type channel. Oxaliplatin is expected to bind to cysteines. Therefore, we explored if there could be a specific effect on single (E418C) and double-cysteine (R362C/F416C) mutated Shaker channels previously shown to be sensitive to cysteine-specific reagents. Neither of these channels were affected by oxaliplatin. The clear lack of effect on the Shaker K channel suggests that oxaliplatin or its monochloro complex has no general surface-charge effect on the channels, as has been suggested before, but rather a specific effect to the channels previously shown to be affected.
Figure 1. Chemical structures. Chemical structures of oxaliplatin, the monochloro monooxalato oxaliplatin complex ([Pt(dach)oxCl]-), and the dichloro oxaliplatin complex (Pt(dach)Cl2).
Figure 2. Shaker wild-type channel. Oxaliplatin does not affect the Shaker wild-type channel. A) Current family in control solution. Voltage steps between -80 mV and 0 mV in steps of 10 mV. Holding voltage = -80 mV. Time between each step is 2 s. Recordings done by the two-electrode voltage clamp technique. B) Current family with 240 μM oxaliplatin added to the extracellular solution. C) Conductance versus voltage curve for the data from A and B.
Figure 3. Cysteine-enriched Shaker channel. Oxaliplatin does not affect a cysteine-enriched Shaker (E418C) channel. A) Current family in control solution. Voltage steps between -40 and +60 mV in steps of 20 mV. Holding voltage = -80 mV. Time between each step is 2 min to allow complete recovery after inactivation [16]. Two-electrode voltage clamp in A and B. B) Current family after complete modification of the positively charged MTSET. This shows that 418C is very sensitive to modification. C) Another control recording similar to that in A. Cut-open oocyte voltage clamp in C and D. D) Addition of 60 μM oxaliplatin does not affect the currents.
Figure 4. Double-cysteine-mutated Shaker channel. Oxaliplatin does not affect a double-cysteine-mutated Shaker (R362C/F416C) channel. A) Current family in control solution. Voltage steps between -80 and +30 mV in steps of 10 mV. Holding voltage = -80 mV. Time between each step is 2 s. B) Current family with 240 μM oxaliplatin added to the extracellular solution. C) Conductance versus voltage curve for the data from A and B. The experiments were carried out in Cl- -containing solutions with the two-electrode voltage clamp technique.
Adelsberger,
The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.
2000, Pubmed
Adelsberger,
The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.
2000,
Pubmed
Benoit,
Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons.
2006,
Pubmed
Broomand,
Molecular movement of the voltage sensor in a K channel.
2003,
Pubmed
,
Xenbase
Börjesson,
Lipoelectric modification of ion channel voltage gating by polyunsaturated fatty acids.
2008,
Pubmed
,
Xenbase
Börjesson,
Structure, function, and modification of the voltage sensor in voltage-gated ion channels.
2008,
Pubmed
Cavaletti,
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat.
2001,
Pubmed
Ehrsson,
Pharmacokinetics of oxaliplatin in humans.
2002,
Pubmed
Elinder,
Localization of the extracellular end of the voltage sensor S4 in a potassium channel.
2001,
Pubmed
,
Xenbase
Elinder,
Metal ion effects on ion channel gating.
2003,
Pubmed
Gamelin,
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
2002,
Pubmed
Geller,
Binding of calcium by organic anions, determined by perturbation of the equilibrium solubility of [14C]calcium oxalate.
1989,
Pubmed
Grolleau,
A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.
2001,
Pubmed
Holmes,
Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.
1998,
Pubmed
Hoshi,
Biophysical and molecular mechanisms of Shaker potassium channel inactivation.
1990,
Pubmed
,
Xenbase
Jerremalm,
Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex.
2004,
Pubmed
Jerremalm,
Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate.
2006,
Pubmed
Kagiava,
The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat.
2008,
Pubmed
Kamb,
Molecular characterization of Shaker, a Drosophila gene that encodes a potassium channel.
1987,
Pubmed
Larsson,
A conserved glutamate is important for slow inactivation in K+ channels.
2000,
Pubmed
,
Xenbase
Luo,
Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
1999,
Pubmed
Mani,
Oxaliplatin: a review of evolving concepts.
2002,
Pubmed
McKeage,
Nucleolar damage correlates with neurotoxicity induced by different platinum drugs.
2001,
Pubmed
Männikkö,
Voltage-sensing mechanism is conserved among ion channels gated by opposite voltages.
2002,
Pubmed
,
Xenbase
Schwarz,
Multiple potassium-channel components are produced by alternative splicing at the Shaker locus in Drosophila.
1988,
Pubmed
Ta,
Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding.
2006,
Pubmed
Taglialatela,
Novel voltage clamp to record small, fast currents from ion channels expressed in Xenopus oocytes.
1992,
Pubmed
,
Xenbase
Webster,
Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.
2005,
Pubmed
Wilson,
Acute oxaliplatin-induced peripheral nerve hyperexcitability.
2002,
Pubmed
Yellen,
An engineered cysteine in the external mouth of a K+ channel allows inactivation to be modulated by metal binding.
1994,
Pubmed